Action NOVO BNOVO NORDISK A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Novo Nordisk A/S

Actions

NOVO B

DK0062498333

Produits pharmaceutiques

Marché Fermé - Nasdaq Copenhagen
Autres places de cotation
 17:20:00 22/04/2025 		Varia. 5j. Varia. 1 janv.
390,00 DKK -7,42% Graphique intraday de Novo Nordisk A/S -10,52% -37,52%
22/04 Les actions européennes reculent alors que les propos anti-Powell de Trump accentuent l'incertitude RE
22/04 NOVO NORDISK : UBS toujours positif ZD

Communiqués

Recherche
Voir les résultats
FDA Issues Warning About Counterfeit Ozempic
22/04
 AQ
FDA warns of fake Ozempic Type 2 diabetes injection drugs
15/04
 AQ
Novo Nordisk A/S : 2024 ( novo nordisk modern slavery statement 2024 )
14/04
 PU
Novo Nordisk A/S : 2024 ( novo nordisk human rights report 2024 )
14/04
 PU
Nanexa publishes annual report for 2024
10/04
 AQ
Canadian scientist wins Breakthrough Prize for discovery of hormone used in Ozempic, Mounjaro
06/04
 AQ
Next-gen biotech: rBIO's approach to affordable insulin solutions
04/04
 AQ
Novo Nordisk announces changes in Executive Management
03/04
 GL
Novo Nordisk A/S : Presentation from Annual General Meeting 2025
31/03
 PU
Novo Nordisk gains rights to novel small molecule inhibitor
31/03
 AQ
Emerging Tech Quartet - PRSO, LXRX, PRTG, RNAZ - Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics
31/03
 AQ
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
29/03
 AQ
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
29/03
 GL
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
29/03
 AQ
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
29/03
 GL
Resolutions from the Annual General Meeting of Novo Nordisk A/S
27/03
 GL
FDA's Semaglutide Shortage Resolution: Legal Implications And Risks For Compounding Pharmacies
27/03
 AQ
Dr. Göran Ando is proposed for election to Initiator Pharma’s Board of Directors and appointed as senior advisor in business development
25/03
 AQ
PUTTING ON THE SQUEEZE Novo Nordisk overtaken as Europe's most valuable firm
25/03
 AQ
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
24/03
 BU
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
24/03
 GL
NVO Deadline: Rosen Law Firm Urges Novo Nordisk A/S (NYSE: NVO) Stockholders to Contact the Firm for Information About Their Rights
22/03
 BU
Lifecare scientific updates: CGM symposium in Bergen, consensus recommendations from the Diabetes Technology Society and presentation of data at ATTD 2025
20/03
 AQ
Novo Nordisk industry membership reinstated
18/03
 AQ
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
10/03
 GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NOVO B
  4. Actualités Novo Nordisk A/S
  5. Communiqués
Etats-Unis

Zonebourse is also available in this country: United States.

Switch edition
Rester sur l'édition actuelle